Nyheder

Lundbeckfonden Ventures nyheder

Lund, Sweden, 08:00 CET, 19 September 2018 – Strategic review has led to important initiatives to strengthen BONESUPPORT’s US and European commercial platforms Excellent progress in creating own distributor network in the US. 18 new distributors contracted. 425 highly motivated sales reps to sell BONESUPPORT’s products from 21 October 2018   European commercial expansion on track...
Cambridge, UK and Indianapolis, US – 14 September 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical trial with BARHEMSYS(TM) (intravenous amisulpride) have been published in the online edition of the leading peer-reviewed journal Anesthesia & Analgesia (Candiotti et al1). Positive headline...
Cambridge, UK and Indianapolis, US – 7 September 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH) announces that it will hold a General Meeting of shareholders on 25 September 2018 at 10.00 a.m. BST at the offices of Stephenson Harwood LLP, 1 Finsbury Circus London EC4M 7SH,  in order to...
Cambridge, UK and Indianapolis, US – 7 September 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH) announces unaudited operating results for the half year ended 30 June 2018. Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and...
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that Julie Feder has joined the company’s leadership team as Chief Financial Officer. In addition, the company announced the addition of Kylie Reynolds as Vice President of Finance, further augmenting Aura’s in-house finance expertise as the company finalizes...
Lund, Sweden, 07:30 CET, 6 September 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that abstracts detailing clinical research using the Company’s CERAMENT platform will feature prominently at the 37th Meeting of the European Bone & Joint Infection Society (EBJIS), which this year takes place on 6th September...
Lund, Sweden, 15:00 CET, 5 September 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, invite journalists, analysts and investors to its Capital Markets Days in Stockholm and London. 19 September 2018 at 9:00am – 12.00pm Stockholm (IVA Conference Center -Wennström-salen -Grev Turegatan 16) 20 September 2018 at 9:30am –...
Lund, Sweden, 11:00 CET, 24 August 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, invites analysts and investors to its Capital Markets Days to take place in Stockholm and London. Capital Markets Days: 19 September 2018 at 9:00am – 12.00 pm (Stockholm) 20 September 2018 at 9:30am – 12.30...
Lund, Sweden, 18:00 CET, 16 August 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that its antibiotic-eluting product CERAMENT G has been approved by Health Canada. CERAMENT G is the first and only CE-marked gentamicin-eluting injectable ceramic bone graft substitute on the market. CERAMENT G sales have been...
1 2 3 45

Lundbeckfonden Ventures

Nyheder

BONESUPPORT highlights significant strategic progress at Capital Market Days in Stockholm and London
20. september 2018
Acacia Pharma Group PLC – ACACIA PHARMA ANNOUNCES POSITIVE BARHEMSYS(TM) DATA PUBLISHED IN LEADING ANAESTHESIA JOURNAL
17. september 2018
Acacia Pharma Group PLC – Acacia Pharma Group plc: Notice of General Meeting of Shareholders
7. september 2018